PubRank

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

Clinical Trial ID NCT00021528

PubWeight™ 114.81‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00021528

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004 6.64
2 Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006 6.00
3 Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006 5.16
4 Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 2003 5.05
5 An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 2005 3.03
6 Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 2011 2.37
7 Prognostic subgroups for citalopram response in the STAR*D trial. J Clin Psychiatry 2014 2.10
8 Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry 2005 1.99
9 Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008 1.92
10 Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2009 1.91
11 A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. Biol Psychiatry 2013 1.90
12 Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry 2001 1.88
13 Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry 2016 1.84
14 Gender differences in depression: findings from the STAR*D study. J Affect Disord 2005 1.80
15 Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression to measure treatment impact and recovery in MDD. JAMA Psychiatry 2013 1.71
16 Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J Clin Psychiatry 2005 1.70
17 Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004 1.64
18 Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry 2013 1.61
19 Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J Clin Psychiatry 2008 1.57
20 Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord 2005 1.49
21 Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry 2003 1.48
22 Inference for optimal dynamic treatment regimes using an adaptive m-out-of-n bootstrap scheme. Biometrics 2013 1.46
23 Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med 2011 1.45
24 Depression is not a consistent syndrome: An investigation of unique symptom patterns in the STAR*D study. J Affect Disord 2014 1.39
25 Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 2009 1.38
26 Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med 2008 1.28
27 Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. Acta Psychiatr Scand 2005 1.27
28 Factors that differentiate early vs. later onset of major depression disorder. Psychiatry Res 2004 1.21
29 Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. Clin Trials 2004 1.20
30 Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol Med 2009 1.13
31 A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial. Gen Hosp Psychiatry 2005 1.12
32 Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort. Am J Addict 2006 1.09
33 Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend 2009 1.06
34 Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trial. J Psychiatr Res 2005 1.04
35 Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013 1.03
36 Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort. Compr Psychiatry 2005 1.02
37 The impact of individual depressive symptoms on impairment of psychosocial functioning. PLoS One 2014 1.02
38 What are 'good' depression symptoms? Comparing the centrality of DSM and non-DSM symptoms of depression in a network analysis. J Affect Disord 2015 1.02
39 Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. Gen Hosp Psychiatry 2004 1.01
40 Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol 2009 0.98
41 Self-report and clinician-rated measures of depression severity: can one replace the other? Depress Anxiety 2012 0.98
42 Age-related characteristics of depression: a preliminary STAR*D report. Am J Geriatr Psychiatry 2005 0.96
43 Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care. J Clin Psychiatry 2010 0.94
44 Characteristics of insured and noninsured outpatients with depression in STAR(*)D. Psychiatr Serv 2005 0.93
45 Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. Psychol Med 2011 0.93
46 Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines. J Psychiatr Res 2004 0.93
47 Poor response to antidepressant medication of patients with depression accompanied by somatic symptomatology in the STAR*D Study. Psychiatry Res 2011 0.92
48 Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort. J Clin Psychiatry 2007 0.91
49 Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC). J Affect Disord 2014 0.90
50 Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry 2010 0.88
51 Impact of fatigue on outcome of selective serotonin reuptake inhibitor treatment: secondary analysis of STAR*D. Curr Med Res Opin 2014 0.88
52 Self-reported premenstrual exacerbation of depressive symptoms in patients seeking treatment for major depression. Psychol Med 2005 0.87
53 Assessing anxious features in depressed outpatients. Int J Methods Psychiatr Res 2011 0.86
54 Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex. Biol Psychiatry 2012 0.86
55 Family history of depression and therapeutic outcome: findings from STAR*D. J Clin Psychiatry 2008 0.86
56 Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D). J Psychiatr Res 2004 0.85
57 Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D). J Affect Disord 2013 0.84
58 Trajectories of individual symptoms in remitters versus non-remitters with depression. J Affect Disord 2013 0.84
59 Sexual satisfaction and quality of life in major depressive disorder before and after treatment with citalopram in the STAR*D study. J Clin Psychiatry 2013 0.84
60 Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up. Acta Psychiatr Scand 2014 0.83
61 Patient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the star*d trial. Depress Anxiety 2013 0.83
62 Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. J Clin Psychiatry 2008 0.82
63 Quality improvement methods as applied to a multicenter effectiveness trial--STAR*D. Contemp Clin Trials 2005 0.82
64 Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry 2003 0.81
65 Changes in depressive symptoms and social functioning in the sequenced treatment alternatives to relieve depression study. J Nerv Ment Dis 2011 0.81
66 Maternal inheritance in recurrent early-onset depression. Psychiatr Genet 2010 0.81
67 Race, genetic ancestry and response to antidepressant treatment for major depression. Neuropsychopharmacology 2013 0.81
68 Increased prevalence of two mitochondrial DNA polymorphisms in functional disease: Are we describing different parts of an energy-depleted elephant? Mitochondrion 2015 0.81
69 Measuring depression over time . . . Or not? Lack of unidimensionality and longitudinal measurement invariance in four common rating scales of depression. Psychol Assess 2016 0.81
70 Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. Eur Neuropsychopharmacol 2012 0.80
71 PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics J 2014 0.79
72 The clinical relevance of self-reported premenstrual worsening of depressive symptoms in the management of depressed outpatients: a STAR*D report. J Womens Health (Larchmt) 2013 0.78
73 Neuronal cell adhesion genes and antidepressant response in three independent samples. Pharmacogenomics J 2015 0.78
74 Retention and attrition among African Americans in the STAR*D study: what causes research volunteers to stay or stray? Depress Anxiety 2013 0.78
75 DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy. J Affect Disord 2014 0.78
76 Prevalence and impact of obsessive-compulsive symptoms in depression: a STAR*D report. J Clin Psychiatry 2015 0.78
77 Motivational deficits in major depressive disorder: Cross-sectional and longitudinal relationships with functional impairment and subjective well-being. Compr Psychiatry 2015 0.77
78 Clinical and sociodemographic characteristics associated with suicidal ideation in depressed outpatients. Can J Psychiatry 2013 0.77
79 The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. J Affect Disord 2015 0.77
80 Additive genetic contribution to symptom dimensions in major depressive disorder. J Abnorm Psychol 2016 0.77
81 The role of the potassium channel gene KCNK2 in major depressive disorder. Psychiatry Res 2014 0.76
82 A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment. J Neural Transm (Vienna) 2014 0.76
83 Clinical and molecular genetics of psychotic depression. Schizophr Bull 2013 0.76
84 Commentary: "Consistent Superiority of Selective Serotonin Reuptake Inhibitors Over Placebo in Reducing Depressed Mood in Patients with Major Depression". Front Psychiatry 2015 0.76
85 Clinical features and drug induced side effects in early versus late antidepressant responders. J Psychiatr Res 2013 0.76
86 Estimating optimal shared-parameter dynamic regimens with application to a multistage depression clinical trial. Biometrics 2016 0.75
87 Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. Int Clin Psychopharmacol 2022 0.75
88 Poster Session IIIWednesday, December 9, 2015. Neuropsychopharmacology 2015 0.75
89 Examining the Impact of Patient-Reported Hope for Improvement and Patient Satisfaction with Clinician/Treatment on the Outcome of Major Depressive Disorder Treatment. Int Neuropsychiatr Dis J 2016 0.75
90 Measuring the individual benefit of a medical or behavioral treatment using generalized linear mixed-effects models. Stat Med 2016 0.75
91 Patient-reported functioning in major depressive disorder. Ther Adv Chronic Dis 2016 0.75
92 Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. BMC Psychiatry 2016 0.75
93 Problems from the past and prevention for the future. Can J Psychiatry 2015 0.75
94 Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial. J Clin Psychiatry 2016 0.75
95 Changes in depression subtypes for women during treatment with citalopram: a latent transition analysis. Arch Womens Ment Health 2016 0.75
96 Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder. Transl Psychiatry 2015 0.75
97 Quality of Life, Functioning, and Depressive Symptom Severity in Older Adults With Major Depressive Disorder Treated With Citalopram in the STAR*D Study. J Clin Psychiatry 2017 0.75
98 Baseline difference between patients' and clinicians' rated illness severity scores and subsequent outcomes in major depressive disorder: analysis of the sequenced treatment alternatives to relieve depression data. J Clin Psychopharmacol 2014 0.75
99 A Novel Mixture Model to Estimate the Time to Drug Effect Onset and Its Association with Covariates. Hum Hered 2016 0.75
Next 100